Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Former JnJ executive...

    Former JnJ executive Marianne De Backer to lead Bayer pharma division

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-09-04T09:30:05+05:30  |  Updated On 16 Aug 2021 4:36 PM IST

    Marianne De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival JnJ, where she led business development activities across different therapeutic areas and regions.


    Frankfurt: Bayer said it hired Johnson & Johnson(JnJ) executive Marianne De Backer to manage acquisitions and licensing deals at its drugs unit, as the German drugmaker turns to outside sources to boost its development pipeline.


    De Backer will take the role of Head of Business Development & Licensing at Bayer's pharmaceuticals division, joining from rival JnJ, where she led business development activities across different therapeutic areas and regions.


    Based in Berkeley, California, the Belgian national will have a more senior role than her predecessor, reporting directly to the head of pharmaceuticals, Stefan Oelrich, and taking a seat on the division's Executive Committee.


    Read Also: Bayer sells Animal Health unit to US drug firm Elanco for USD 7.6 billion


    Bayer said last year it would lean more strongly on external firms and institutions for a better drug development pipeline, which most analysts regard as too thin to make up for an expected decline in revenues from its two pharma bestsellers from about 2024.


    Bayer has recently agreed on deals to sell a stake in a chemical park operator, consumer health brands Dr Scholl's and Coppertone, as well as it's animal health unit in a bid to reduce the debt burden from its $63 billion takeovers of Monson.


    Read Also: Bayer mediator dismisses report of USD 8 billion Roundup settlement

    backerBayerBerkeleyBusiness Developmentconsumer brandconsumer healthDe Backerdr schollHealthcareJnJJohnsonlisencingMarianne De Backerpharmapharma companypharma divisionpharma newsStefan Oelrich
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok